share_log

Clearmind Medicine | CORRESP: CORRESP

SEC announcement ·  Feb 15 11:21
Summary by Futu AI
Clearmind Medicine Inc., a biotechnology company, has formally requested the Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form F-1. The company aims for the Registration Statement to become effective on February 16, 2024, at 4:00 p.m. Eastern Time. This request was made under Rule 461 of the Securities Act of 1933, as amended. Clearmind Medicine has authorized its counsel, Greenberg Traurig, P.A., and specifically David Huberman, to communicate with the SEC regarding the effectiveness of the Registration Statement and to make any necessary modifications or withdrawals to the acceleration request.
Clearmind Medicine Inc., a biotechnology company, has formally requested the Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form F-1. The company aims for the Registration Statement to become effective on February 16, 2024, at 4:00 p.m. Eastern Time. This request was made under Rule 461 of the Securities Act of 1933, as amended. Clearmind Medicine has authorized its counsel, Greenberg Traurig, P.A., and specifically David Huberman, to communicate with the SEC regarding the effectiveness of the Registration Statement and to make any necessary modifications or withdrawals to the acceleration request.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.